tirzepatide surpass-5 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Reduction of prevalence of patients

A weekly semaglutide dose of 7.2 mg has been shown to markedly enhance weight loss and improve health outcomes for adults with obesity, including those who also have type 2 diabetes (T2D)

Intraperitoneal insulin tolerance (ITT) (a) , baseline-corrected area of curve (AOC) (b) and HOMA-IR (c) of male 34-wk old DIO mice treated for 14-days with Vhcl or 50 nmol/kg of either GLP-1RA, Tesaglitazar or GLP-1RA/Tesaglitazar

Gut Microbiome Support: A healthy gut microbiome can contribute to regular bowel movements

Should a supplement user use a supplement that is produced in the same facility as a DHEA supplement, there is a risk for cross-contamination

Protein phosphatases belong to two major families of phosphatases: serine/threonine protein phosphatases and protein tyrosine phosphatases (PTPs)